CHICAGO — In this video from Eyecelerator@AAO, Opthea CEO Megan Baldwin, PhD, discusses updates for OPT-302, a therapy targeting a new mechanism of action for the treatment of wet age-related macular degeneration.
“We’re excited about it because it targets VEGF-C and VEGF-D, which are not currently targeted by the existing standard of care treatments,” she said.